Wanda Phipatanakul Laboratory | Overview
Dr. Phipatanakul was the Boston pediatric PI for the NHLBI U10 AsthmaNet during its 9-year cycle since 2009. In AsthmaNet, among other high impact investigations published in NEJM and JAMA, her lab laid to rest a longstanding controversy in the field, showing that acetaminophen use does not confer increased asthma morbidity in children (NEJM 2016, senior corresponding author). She is currently the Boston pediatric site PI for the Severe Asthma Research Program and the PreCISE network, evaluating precision medicine in severe asthma. Having lead the Center in the Childhood Asthma in Urban Settings and Atopic Dermatitis Research network, Dr. Phipatanakul also served as Project Lead for the NIH/NIAMS Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium, which validates pediatric reported outcomes in multiple conditions (i.e. asthma, cancer, inflammatory bowel disease, lupus, juvenile arthritis, chronic kidney disease, sickle cell disease, diabetes and atopic dermatitis) and the competitively awarded PEPR Geocoding core that leverages neighborhood factors and outcomes.
In addition to being the PI for the School Inner-City Asthma Intervention Study (SICAS2), Dr. Phipatanakul serves as overall PI of a nationwide 14-center asthma prevention U01 study evaluating omalizumab (anti-IgE) in preventing the allergic asthma march in high risk 2-3 year olds, which is the first study of its kind, and brings a national recognition and a core of unique translational/mechanistic investigation to Boston Children's.
Her role in NIH consortia has positioned Boston Children’s Hospital as the premier pediatric collaborative research enterprise in the field. She has produced over 300 publications and delivered over 250 invited lectures nationally and internationally to disseminate her work with Boston Childrens Hospital. She was elected into the American Society of Clinical Investigation in 2017, an honor society for exemplary research.
Dr. Phipatanakul’s long-standing relationship with community, comprehensively evaluating the role of school-specific exposures and asthma, allergies, and food allergies allows her to work towards incorporating public policy and school-based asthma/allergy management initiatives.